18 / 30
Objective Response Rates:
Independent Review
n (%)
Lenvatinib (n=261)
Placebo (n=131)
Objective Response Rate
169 (64.8)
2 (1.5)
95% CI
59.0–70.5
0.0–3.6
P
-value
<0.0001
Complete response
4 (1.5)
0
Partial response
165 (63.2)
2 (1.5)
Stable disease
60 (23.0)
71 (54.2)
Stable disease ≥23 weeks
40 (15.3)
39 (29.8)
Progressive disease
18 (6.9)
52 (39.7)
Not evaluable/Unknown
14 (5.4)
6 (4.6)
Disease Control Rate
229 (87.7)
73 (55.7)
95% CI
83.8–91.7
47.2–64.2
P
-value
<0.0001
Clinical Benefit Rate
209 (80.1)
41 (31.3)
95% CI
75.2–84.9
23.4–39.2
P
-value
<0.0001
CI, confidence interval; NR, not reached.
Median time to lenvatinib response: 2.0 months (range, 1.9–3.5 months)
Median duration of lenvatinib response: NR (95% CI, 16.8–NR)
Schlumberger M, et al. N Engl J Med 2015;372:621-30. DOI: 10.1056/NEJMoa1406470